DPRO:NASDAQDraganfly Inc. Analysis
Data as of 2026-06-09 - not real-time
$6.42
Latest Price
8/10Risk
Risk Level: High
Executive Summary
Draganfly Inc. (DPRO) posted a 49.4% YoY revenue surge to $8.5 M, driven by new military and strategic vertical contracts, yet the company remains loss‑making with a gross margin near breakeven and operating margins deep in the negative. The stock trades at a forward P/E of –12.9 and a price‑to‑book of 1.86, while the price‑to‑sales ratio of 27.6 suggests the market is pricing in substantial growth expectations. Technicals show the 20‑day SMA (6.31) above the 50‑day SMA (5.78) indicating short‑term momentum, but the price sits below the 200‑day SMA (7.08) and the MACD histogram is marginally negative, reflecting a neutral to slightly bearish medium‑term bias. Volatility is extreme at 91% over 30 days and beta exceeds 3, underscoring heightened market risk. Despite a strong analyst consensus of “strong buy” and an 81% upside potential, the company’s cash flow is negative and ROE is –32%, raising concerns about sustainability. The current market price of $6.42 sits comfortably above the identified support at $5.06 but well below the recent high of $8.28, leaving room for upside if the growth trajectory holds.
Overall, DPRO offers a speculative play on rapid revenue expansion and defense‑related contracts, balanced against deep losses, high volatility, and significant execution risk. Investors should weigh the upside potential against the company’s cash‑burn and the broader regulatory environment for drone technology.
Overall, DPRO offers a speculative play on rapid revenue expansion and defense‑related contracts, balanced against deep losses, high volatility, and significant execution risk. Investors should weigh the upside potential against the company’s cash‑burn and the broader regulatory environment for drone technology.
Market Outlook
Short Term
< 1 yearPositive
Model confidence: 6/10
Key Factors
- Revenue growth of ~50% YoY
- Price above immediate support level
- Short‑term SMA crossover indicating momentum
Medium Term
1–3 yearsNeutral
Model confidence: 5/10
Key Factors
- Negative earnings and cash flow
- MACD and price below long‑term SMA
- High volatility and beta amplifying risk
Long Term
> 3 yearsPositive
Model confidence: 7/10
Key Factors
- Strategic military partnerships expanding addressable market
- Projected upside of over 80% based on analyst targets
- Potential turnaround if margins improve and cash burn slows
Key Metrics & Analysis
Financial Health
Revenue Growth49.40%
Profit Margin-296.44%
P/E Ratio-12.9
ROE-32.03%
ROA-18.48%
Debt/Equity0.15
P/B Ratio1.9
Op. Cash Flow$-28182586
Free Cash Flow$-24081570
Industry P/E33.3
Technical Analysis
TrendNeutral
RSI51.1
Support$5.06
Resistance$8.28
MA 20$6.31
MA 50$5.78
MA 200$7.08
MACDBearish
VolumeIncreasing
Fear & Greed Index87.64
Valuation
Target Price$11.63
Upside/Downside81.21%
GradeUndervalued
TypeGrowth
Risk Assessment
Beta3.35
Volatility91.42%
Sector RiskHigh
Reg. RiskMedium
Geo RiskMedium
Currency RiskLow
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.